EP0346831A2 - Antibiotics and process for producing them - Google Patents
Antibiotics and process for producing them Download PDFInfo
- Publication number
- EP0346831A2 EP0346831A2 EP89110689A EP89110689A EP0346831A2 EP 0346831 A2 EP0346831 A2 EP 0346831A2 EP 89110689 A EP89110689 A EP 89110689A EP 89110689 A EP89110689 A EP 89110689A EP 0346831 A2 EP0346831 A2 EP 0346831A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- methanol
- antibiotics
- mixture
- antibiotic
- aqueous solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/06—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using actinomycetales
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07G—COMPOUNDS OF UNKNOWN CONSTITUTION
- C07G11/00—Antibiotics
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/465—Streptomyces
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/886—Streptomyces
Definitions
- the present invention relates to antibiotic substances arbitarily named "AB-011 Antibiotics" and to the main components thereof, i.e. antibiotic AB-011a and antibiotic AB-011b.
- the present invention relates to the process for preparing said antibiotics, by means of the fermentation of Streptomyces s.p. NCIB 12629, and to their use in the treatment of infective diseases caused by microorganisms susceptible to said antibiotics.
- AB-011 antibiotics are different from the known antibiotics.
- the term "AB-011 Antibiotics" used in the present invention is meant to define a mixture which comprises all of the components endowed with biological activity, for example antifungal activity, produced by the fermentation of Streptomyces s.p. NCIB 12629 under the conditions specified in the following.
- Said active components comprise, but are not limited to, those designated as AB-011a and AB-011b which can be isolated from the mixture.
- the number and the mutual ratios of the components which form the AB-011 antibiotics may vary as a function of the fermentation conditions and of the bacterial strain used.
- the present invention is not limited to the use of Streptomyces s.p. NCIB 12629, but also comprises the use of either natural or artificial mutants and variants of the above microorganism, provided that they produce the AB-011 antibiotics.
- the present invention is directed to the AB-011 antibiotics obtainable by means of the controlled cultivation under aerobic conditions of Streptomyces s.p. NCIB 12629, or of an equivalent mutant thereof, in an aqueous nutrient cultivation medium, containing sources of carbon and nitrogen as well as inorganic salts, and subsequent separation of said antibiotics and of the main components thereof, i.e. antibiotics AB-011a and AB-011b.
- AB-011a a component of the AB-011 antibiotics, is a powder of light yellow colour, characterized by: (a) an approximate elemental analysis, determined on a sample left to stand under vacuum for 2 hours at 40°C as follows: said analysis revealing neither sulfur nor phosphorus; (b) a molecular weight of about 1,197.65, as determined by FAB-MS spectroscopy, yielding a peak at 1,196.65, corresponding to (M-H) ⁇ , under the following operating conditions: - Negative ions, FAB, Xe at 9.5 kV - Matrix: glycerol - Finnigan Mat 8424; (c) an U.V.
- AB-011b a component of AB-011 antibiotics, is a powder of deep yellow colour, characterized by: (a) an approximate elemental analysis, determined on a sample left to stand under vacuum at 40°C for 2 hours, as follows: carbon: 58.51% hydrogen: 8.14% nitrogen: 1.03%; said analysis revealing neither sulfur nor phosphorus; (b) a molecular weight of about 1,181 as determined by FAB-MS spectroscopy, affording a peak at 1,180, corresponding to (M-H)-, under the following operating conditions: - Negative ions, FAB, Xe at 9.5 kV - Matrix: glycerol - Finnigan Mat 8424; (c) the U.V.
- the microorganism was isolated from a sample of soil collected at Varzo (Novara), catalogued under the designation SD18.
- Table A The morphological characteristics of the strain are listed in Table A (the names of the culture media are those assigned by the International Streptomyces Program).
- Table A ISP Code Culture Medium Description M2 Malt Extract Agar High, rough colonies with a base mycelium of light colour, the spores are plentiful and are of light yellow colour. M3 Oat Meal Agar Low colonies, "radiated” base mycelium of light colour, white spores. M4 Starch Agar Scarce growth, white spores. M5 Glycerol Asparagine Agar Scarce growth, white spores. M6 Peptone Iron Agar Not very high colonies, light-coloured mycelium, white spores.
- Table C Compound Growth 2-keto-gluconate negative adonitol negative arabinose negative cellobiose negative fructose positive galactose negative glycerol positive glucose positive inositol positive lactose negative maltose negative mannitol positive melezitose negative methyl-D-glucoside negative N-acetyl-D-glucosamine positive raffinose negative rhamnose positive saccharose negative sorbitol negative trehalose positive xylitol negative xylose negative
- Streptomyces s.p. NCIB 12629 can undergo mutations.
- artificial variants or mutants can be obtained by treatment with various known mutagens, such as X rays or U.V. light, high-frequency waves and chemical substances, like nitrous acid, halogenated alkylamines, nitroso-guandine, camphor, and the like.
- mutagens such as X rays or U.V. light, high-frequency waves and chemical substances, like nitrous acid, halogenated alkylamines, nitroso-guandine, camphor, and the like.
- the process for the preparation of AB-011 antibiotics comprises the cultivation of Streptomyces s.p. NCIB 12629, or of an equivalent mutant thereof, under conditions of controlled aerobic fermentation in an aqueous nutrient medium, and the subsequent separation of said antibiotics by means of per se known methods.
- nutrient culture media or fermentation broths those which are commonly employed for the production of antibiotics can be used; however, some culture media are preferred.
- Said cultivation media should contain sources of carbon and nitrogen which can be assimilated by the microorganisms of the genus Streptomyces , and should, furthermore, show low levels of inorganic salts. Additionally, the media should contain traces of those metals which are necessary for the growth and the development of the microorganisms. Said metals may already be present as impurities in the sources of carbon or of protein nitrogen supplied for the bacterial growth or, optionally, they can be added to the culture medium.
- carbohydrates which may be of the saccaride type, such as, e.g., glucose or fructose, and of the starch type, or products similar to those types from an industrial point of view, such as, e.g. dextrin, soluble starch, or polyalcohols, such as, e.g. glycerol.
- saccaride type such as, e.g., glucose or fructose
- starch type such as, e.g., glucose or fructose
- products similar to those types from an industrial point of view such as, e.g. dextrin, soluble starch
- polyalcohols such as, e.g. glycerol
- the concentration of the carbon source in the culture medium generally depends on the type and amount of the other ingredients contained in said medium; anyway, concentrations of from 0.5 to 5% by weight are generally satisfactory.
- nitrogen source both proteinic extracts such as, e.g., yeast extract, casein hydrolisate, or peptone, and meals, such as, e.g. soybean meal, or commercially available industrial pro ducts for that purpose, such as, e.g., proflo, corn steep liquor or distillers' solubles, can be used.
- These compounds can be used individually or in combination, at concentrations in the culture medium of from 0.1% to 4% by weight.
- inorganic salts there can be used, for example, sodium salts, potassium salts, magnesium salts, ammonium salts and calcium salts, such as phosphates, sulfates, chlorides, carbonates and nitrates.
- the trace metals can be, e.g., cobalt, manganese, iron, and the like.
- Some culture media display a particular ability to stimulate the production of AB-011 antibiotics by Streptomyces s.p. NCIB 12629; among these, for example, the following aqueous formulations can be mentioned, which have been employed in the following preparation Examples.
- P CULTURE MEDIUM Ingredients Concentration g/l starch 20 glucose 10 calcium carbonate 3 casein hydrolysate 2 proflo (cotton seed flour) 2 yeast extract 2 meat extract 2 V CULTURE MEDIUM Ingredients Concentration g/l tryptone 10 meat and liver peptone 10 glucose 5 yeast extract 5 K2HPO4 1 S CULTURE MEDIUM Ingredients Concentration g/l soluble starch 10 glucose 5 potassium nitrate 2 sodium chloride 2 monobasic potassium phosphate 2 hydrolysed casein 1 calcium carbonate 1 magnesium sulfate heptahydrate 0.5 iron sulfate heptahydrate 0.01
- the strain of Streptomyces s.p. NCIB 12629 can be cultivated at temperatures of from 20°C to 35°C, preferably of from 25°C to 30°C.
- the pH value generally is within the range of from about 5 to about 9.
- the sterile air which is injected into the culture medium is generally used in such amounts as to maintain in the medium an oxygen concentration equal to, or higher than, 20% of the saturation value.
- the production of the antibiotics, during the fermentation, can be monitored by means of antibiotic activity tests on broth samples.
- the fermentation is carried out for a time sufficient for obtaining a substantial antibiotic activity; 72-120 hours are generally sufficient for that purpose.
- the AB-011 antibiotics and the main components thereof i.e. antibiotics AB-011a and AB-011b
- Such methods include, e.g., extraction with solvents, precipitation with non-solvents, ultrafiltration, column chromatography, silica-gel chromatography, cellulose chromatography, reverse-phase chromatography, chromatography on non-ionic, macroporous resins, and the like.
- the antibiotics produced during the fermentation can be found in the culture broth and/or in the mycelium mass.
- a preferred method for recovering the AB-011 antibiotics consists in filtering off the mycelium mass from the culture broth, subjecting the mycelium thus separated to an extraction with acetone or methanol and concentrating the extract under vacuum until complete removal of the solvent. Thereby an aqueous suspension is obtained, while suspension is combined with the culture broth.
- the resulting solution containing the AB-011 antibiotics is filtered through fibreglass-paper filters and is then percolated on a column of a non-ionic polystyrene resin, such as, e.g., XAD-2 (Rohm & Haas Co.), which resin adsorbs the AB-011 antibiotics.
- a non-ionic polystyrene resin such as, e.g., XAD-2 (Rohm & Haas Co.
- the resin is then washed with two volumes, based on its bed, of water, and thereafter is eluted with three volumes, also based on its bed, of an 8:2 (V/V) mixture of acetone:water.
- Both pure AB-011a and pure AB-011b are then isolated from the crude product by means of reverse phase chromatography, employing a column packed with silica (MATREX Silica C18 marketed by Amicon Europe, Lausanne, Switzerland) with an eluent system formed by an eluent "A” consisting of water containing 25 millimol per litre of KH2PO4 and 7 millimol per litre of tetramethylammonium chloride, and by an eluent "B” consisting of methanol, using a linear gradient of from 50% up to 80% of eluent "B” in eluent "A".
- silica MATREX Silica C18 marketed by Amicon Europe, Lausanne, Switzerland
- AB-011a and AB-011b separated from their respective solutions as described above are suspended in water and centrifuged again and, after removing the supernatant solutions and drying under vacuum at 40 C for 2 hours, pure antibiotic AB-011a and pure antibiotic AB-011b antibiotic, resp., are obtained.
- the AB-011 antibiotics, and the components thereof, i.e., AB-011a and AB-011b, are endowed with antimicrobial activity and, particularly, antifungal activity.
- AB-011 Antibiotics ⁇ g/ml
- Botrytis cinerea 17 Cercospora beticola 100 Cercosporella herpotrichoides 30 Colletotrichum coffeanum 30 Fusarium moniliforme 30 Fusarium roseum 8 Helminthosporium gramineum 100 Helminthosporium teres 1.5 Helminthosporium sativum 3 Piricularia oryzae 25 Pythium irregulare 100 Rhizoctonia solani 20 Sclerotium cepivorum 3 Septoria nodorum 6 Ustilago maydis 20 Candida albicans 3.5 Sarcina lutea 0.3
- the fungicidal activity in vivo was measured by the following method.
- the AB-011 antibiotics in water-acetone solution (20% V/V) were sprayed onto the lower sides of leaves of plants grown in pots inside a conditioned room.
- Table E Fungus AB-011 Antibiotics concentration, g/l Preventive activity Plasmopara viticola 0.5 100 0.125 100 0.06 100 Sphaeroteca fuliginea 0.5 85 0.125 40 0.06 0 Botrytis cinerea 0.5 100 0.125 70 0.06 15
- the antibiotics according to the present invention are preferably employed in the form of suitable compositions.
- compositions contain, beside an antibiotic according to the present invention as their active principle, inert solid carriers (e.g., kaolin, silica, talc, attapulgite, diatomaceous earth, etc.), or inert liquid carriers (organic solvents, vegetable or mineral oils, water and mixtures thereof), and possibly other additives which are conventionally used in the art of formulations, such as surfactants, suspending agents, dispersants and wetting agents.
- inert solid carriers e.g., kaolin, silica, talc, attapulgite, diatomaceous earth, etc.
- inert liquid carriers organic solvents, vegetable or mineral oils, water and mixtures thereof
- additives which are conventionally used in the art of formulations, such as surfactants, suspending agents, dispersants and wetting agents.
- compositions in case of particular application requirements, or in order to expand the range of action of the compositions, other active ingredients, such as other insecticides, herbicides, fungicides, or fertilizers can be added to the present compositions.
- the applied doses vary as a function of different factors, such as the type and the degree of infestation, the type of composition used and climatic and environmental factors.
- the resulting culture was used to inoculate a fermenter (volume 10 litres) containing 7 litres of medium "S" to which 0.01 g/l of Tween 2000 were added as antifoaming agent, under the following conditions: temperature 29°C, air flow rate 120 litres/hour, rate of stirring 320 rpm, fermentation time 96 hours.
- the resulting fermentation broth was filtered through paper and the mycelium was separated.
- the acetone extract was concentrated under vacuum until the solvent was completely removed and the residual aqueous solution was combined with the previously filtered broth.
- the resulting solution was ultrafiltered through a GR-61 membrane (cut-off 20,000), until 3.2 litres remained in the retained fraction.
- the retained fraction was then diluted to 25 litres with water, and was ultrafiltered again, under the same conditions, whereby a volume of permeate of 20.5 litres was obtained.
- the second retained fraction (4.0 litres), was scarcely active in the activity test (the activity was determined by measuring the Botrytis growth inhibition halo over agar) and therefore was discarded.
- the first ultrafiltrate of 25 litres was concentrated on a GR-90 membrane (cut-off 2000), until 3.6 l remained in the retained fraction, while the ultrafiltrate (21.0 l) was scarcely active on Botrytis and was discarded.
- the retained fraction contained 60% of the initial activity.
- the second ultrafiltration permeate (20.5 l) was concentrated on a GR-90 membrane (cut-off 2000) in the same way as described above, and the residual 3.0 litres contained about 30% of the initial activity.
- the GR-61 and GR-90 membranes belong to the types sold by DDS-Nakskov (Danmark) and were used on a Lab-20 module also marketed by said company.
- the two retained fractions (3.6 l + 3.0 l) were combined and percolated on a column (diameter 45 mm; height of resin bed 30 cm) of non-ionic polystyrene resin XAD-2 (Rohm & Haas Co.), which adsorbed the AB-011 antibiotics.
- a column diameter 45 mm; height of resin bed 30 cm
- non-ionic polystyrene resin XAD-2 Rosorbed the AB-011 antibiotics.
- an inlet flow rate 100 ml/hour was maintained.
- the resin subsequently was washed with two volumes, based on its bed, of water, and was then eluted with 3 volumes, also based on its bed, of an (8:2 V/V) acetone/water mixture.
- AB-011a was collected in a volume of 320 ml in the elution range between 3000 and 3320 ml, while AB-011b was collected in a volume of 700 ml in the elution range between 3700 and 4400 ml.
- the culture broth was centrifuged in order to separate it from the mycelium, and was then used for the biological tests.
- the culture was incubated for 72 hours on a rotary shaker (180 rpm) at 28 C.
- This culture then was incubated for 72 hours on a rotary shaker (180 rpm) at 28°C. Thereafter the incubated culture was inoculated in a 100 ml Erlenmeyer flask containing 20 ml of the "P" medium up to a concentration of 5% and the whole mixture was incubated for 120 hours under the conditions given in Ex ample 2.
- the culture broth was treated in the same way as described in Example 2 and was subjected to the biological tests.
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Communicable Diseases (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
- The present invention relates to antibiotic substances arbitarily named "AB-011 Antibiotics" and to the main components thereof, i.e. antibiotic AB-011a and antibiotic AB-011b.
- Furthermore, the present invention relates to the process for preparing said antibiotics, by means of the fermentation of Streptomyces s.p. NCIB 12629, and to their use in the treatment of infective diseases caused by microorganisms susceptible to said antibiotics.
- The AB-011 antibiotics are different from the known antibiotics.
The term "AB-011 Antibiotics" used in the present invention is meant to define a mixture which comprises all of the components endowed with biological activity, for example antifungal activity, produced by the fermentation of Streptomyces s.p. NCIB 12629 under the conditions specified in the following. - Said active components comprise, but are not limited to, those designated as AB-011a and AB-011b which can be isolated from the mixture.
- It is self-evident that the number and the mutual ratios of the components which form the AB-011 antibiotics may vary as a function of the fermentation conditions and of the bacterial strain used.
- Furthermore, it is to be understood that the present invention is not limited to the use of Streptomyces s.p. NCIB 12629, but also comprises the use of either natural or artificial mutants and variants of the above microorganism, provided that they produce the AB-011 antibiotics.
- Therefore, the present invention is directed to the AB-011 antibiotics obtainable by means of the controlled cultivation under aerobic conditions of Streptomyces s.p. NCIB 12629, or of an equivalent mutant thereof, in an aqueous nutrient cultivation medium, containing sources of carbon and nitrogen as well as inorganic salts, and subsequent separation of said antibiotics and of the main components thereof, i.e. antibiotics AB-011a and AB-011b.
- AB-011a, a component of the AB-011 antibiotics, is a powder of light yellow colour, characterized by:
(a) an approximate elemental analysis, determined on a sample left to stand under vacuum for 2 hours at 40°C as follows: said analysis revealing neither sulfur nor phosphorus;
(b) a molecular weight of about 1,197.65, as determined by FAB-MS spectroscopy, yielding a peak at 1,196.65, corresponding to (M-H)⁻, under the following operating conditions:
- Negative ions, FAB, Xe at 9.5 kV
- Matrix: glycerol
- Finnigan Mat 8424;
(c) an U.V. absorption spectrum shown in Figure 1 of the attached drawings. Said spectrum shows absorbance maxima of 2.269 at 350.4 nm; 2.197 at 332.6 nm; 1.403 at 317.3 nm; 0.679 at 303.3 nm; 0.118 at 381.1 nm; and 0.097 at 405.6 nm, measured at a concentration of 0.029 mg/ml in methanol;
(d) an I.R. absorption spectrum (KBr pellet) as shown in Figure 2 of the attached drawings, exhibiting the following absorption maxima (cm⁻¹) :
3421, 2960, 2930, 2855, 2035, 1718, 1634, 1570, 1448, 1403, 1383, 1340, 1302, 1268, 1168, 1063, 1036, 1009, 989, 906, 848, 794, 575, 526, 473;
(e) an ¹H-NMR spectrum recorded on a BRUKERAM 300 MHz spectrometer in hexa-deutero-dimethylsulfoxide (DMSO-d6) and shown in Figure 3, which spectrum exhibits the following signals : (The chemical shifts were indirectly based on TMS = 0.00 ppm (δTMS) by using the central peak of hexa-deutero-dimethylsulfoxide at δTMS = 2.56 ppm as internal reference.)
δTMS (ppm) : 6.45-6.10* (m, 8H); 5.92 (m, 1H); 5.69 (m, 1H); 5.41 (m, 2H); 5.15 (m, 1H), 4.92 (m, 1H); 4.77-4.22 (m, 6H); 4.22-3.45* (m. 8-10H); 3.37-3.07* (m, 6-7H); 3.02 (t,1H); 2.93 (t, 1H); 2.88-2.72* (m, 3H); 2.45-2.27* (m, 3-4H); 2.27-2.05* (m, 3H); 2.05-1.85* (m, 3H); 1.85-1.66* (m, 1H); 1.66-1.15* (m, 30-33H); 1.10 (d, 3H); 0.99 (d, 3H); 0.90 (m, 6H).
(The number of hydrogen atoms assigned to the signals marked with an asterisk is only tentative, in that it might be affected by an error.)
(f) a ¹³C-NMR spectrum recorded on a BRUKERAM 300 MHz spectrometer in hexa-deutero-dimethylsulfoxide (DMSO-d6) and shown in Figure 4, which spectrum exhibits the following signals: (The chemical shifts were indirectly based on TMS = 0.00 ppm (δTMS) by using the central peak of hexa-deutero-dimethylsulfoxide at δTMS = 39.85 ppm as internal reference. The data as to the multiplicity of the signals were obtained by means of DEPT tests at 45, 90 and 135.)
δTMS (ppm) : 208.6 (s); 176.3 (s); 170.3 (s); 135.8 (d); 134.6 (d); 133.5 (d); 133.2 (d); 132.9 (d); 132.7 (d); 131.7 (d); 131.4 (d); 130.0 (d); 129.5 (d); 100.3 (d); 99.8 (d); 97.4 (s); 97.3 (d); 87.1 (d); 84.4 (d); 79.9 (d); 75.0 (d); 73.5 (d); 73.1 (d); 72.1 (d); 70.7 (d); 70.0 (d); 69.0 (d); 67.1 (d); 66.1 (d); 65.9 (d); 64.0 (d); 58.1 (d); 56.9 (q); 56.3 (d); 51.6 (t); 50.5 (t); 44.7 (t); 43.0 (t); 42.5 (t); 39.7 (d); 39.4 (d); 39.0 (t); 37.5 (t); 36.3 (t); 34.4 (t); 32.1 (t); 31.7 (t); 29.3 (t); 18.0 (q); 17.9 (q); 17.1 (q); 16.0 (q); 11.5 (q).
(Furthermore, some peaks - marked with an asterisk in Figure 4 - were obtained whose attribution to antibiotic AB-011a is uncertain in that they are of variable intensity as a function of the origin of the analysed sample: said peaks might originate from decomposition products of the actual product; the following is a list of said peaks:
δTMS (ppm) : 70.9 (d); 68.9 (d); 31.5 (t); 29.0 (t); 28.8 (t); 28.3 (t); 24.7 (t); 22.8 (q); 22.3 (t); 18.0 (t); 14.2 (q).)
(g) retention coefficients in thin-layer chromatography on silica (Kieselgel) plates of the type 60 F 254 (Merck-Schuchardt) and on reverse-phase silica plates of the type RP-18 F 254 (Merck-Schuchardt) in the following eluent systems and compared to antibiotic AB-011b (distance covered by eluent: 15 cm):Plate Eluent R f (AB-011a) R f (AB-011b) RP-18 A 0.29 0.22 RP-18 B 0.44 0.35 RP-18 C 0.13 0.08 RP-18 D 0.27 0.20 silica E 0.25 0.32 silica F 0.0 0.0
Visualization: - A. Fluorescence in U.V. light (366 nm)
- B. Anisaldehyde - Thin Layer Chromatography - page 205 (T-27 reactant)
- C. o-Aminophenol - Thin Layer Chromatography - page 201 (T-11 reactant) Author: Justus G. Kirchner - 2nd Edition Publisher: John Wiley & Sons.
- AB-011b, a component of AB-011 antibiotics, is a powder of deep yellow colour, characterized by:
(a) an approximate elemental analysis, determined on a sample left to stand under vacuum at 40°C for 2 hours, as follows:carbon: 58.51% hydrogen: 8.14% nitrogen: 1.03%;
(b) a molecular weight of about 1,181 as determined by FAB-MS spectroscopy, affording a peak at 1,180, corresponding to (M-H)-, under the following operating conditions:
- Negative ions, FAB, Xe at 9.5 kV
- Matrix: glycerol
- Finnigan Mat 8424;
(c) the U.V. absorption spectrum shown in Figure 6 of the attached drawings.
Said spectrum shows absorbance maxima of 2.872 at 349.9 nm; 2.747 at 332.4 nm; 1.999 at 316.9 nm; 0.987 at 303.3 nm; measured at a concentration of 0.04 mg/ml in methanol;
(d) an I.R. absorption spectrum (KBr pellet) as shown in Figure 7 of the attached drawings, exhibiting the following absorption maxima (cm⁻¹):
3415, 2926, 2855, 2060, 1721, 1634, 1568, 1450, 1406, 1383, 1302, 1264, 1190, 1168, 1063, 1036, 1007, 988, 906, 847, 804, 722, 664, 618, 576, 509, 471, 446;
(e) an ¹H-NMR spectrum recorded on a BRUKERAM 300 MHz spectrometer in hexa-deutero-dimethylsulfoxide (DMSO-d6) and shown in Figure 8 of the attached drawings, said spectrum exhibiting the following signals:
(The chemical shifts were indirectly based on TMS = 0.00 ppm (δTMS) by using the central peak of hexa-deutero-dimethylsulfoxide at δTMS = 2.56 ppm as internal reference.)
δTMS (ppm) : 6.45-6.05* (m, 8H); 5.93 (m, 1H); 5.70 (m, 1H); 5.40 (m, 2H); 5.13 (m, 1H); 4.73-4.30 (m, 6H); 4.27-3.45* (m, 8-9H); 3.37-3.09* (m, 6-7H); 3.02 (t, 1H); 2.94 (t, 1H); 2.75-2.60* (m, 1H); 2.44-2.28* (m, 3H); 2.28-1.81 (m, 7-8H); 1.81-1.47* (m, 5H); 1.47-1.16* (m, 30-33H); 1.11 (d, 3H); 0.99 (d, 3H): 0.91 (m, 6H).
(The number of hydrogen atoms assigned to the signals marked with an asterisk is only tentative in that it might be affected by error.)
(f) a ¹³C-NMR spectrum recorded on a BRUKERAM 300 MHz spectrometer in hexa-deutero-dimethylsulfoxide (DMSO-d6) and shown in Figure 9 of the attached drawings, said spectrum exhibiting the following signals:
(The chemical shifts were indirectly based on TMS = 0.00 ppm (δTMS) by using the central peak of hexa-deutero-dimethylsulfoxide at δTMS = 39.85 ppm as internal reference. The data as to the multiplicity of the signals were obtained by means of DEPT tests at 45, 90 and 135.)
δTMS (ppm) : 208.7 (s); 176.3 (s); 174.9 (s); 170.4 (s); 135.7 (d); 134.7 (d); 133.5 (d); 133.3 (d); 132.9 (d); 132.7 (d); 131.7 (d); 131.5 (d); 130.0 (d); 129.5 (d); 100.3 (d); 100.0 (d); 97.4 (s); 96.9 (d); 87.2 (d); 84.5 (d); 80.0 (d); 75.1 (d); 74.9 (d); 73.1 (d); 72.2 (d); 70.7 (d); 70.0 (d); 69.0 (d); 68.5 (d); 67.8 (d); 67.1 (c); 65.9 (d); 65.7 (d); 63.9 (d); 58.1 (d); 56.9 (q); 56.2 (d); 51.5 (t); 50.7 (t); 48.5 (t); 44.7 (t); 42.5 (t); 39.1 (t); 38.5 (t); 38.0 (t); 36.3 (t); 34.1 (t); 32.3 (t); 31.8 (t); 31.6 (t); 29.3 (t); 18.1 (q); 18.0 (q); 17.9 (q); 17.4 (q); 16.3 (q); 11.6 (q).
(Furthermore, some peaks - marked with an asterisk in Figure 9 - were obtained, whose attribution to antibiotic AB-011b is uncertain in that they are of variable intensity as a function of the origin of the analysed sample: said peaks might originate from decomposition products of the actual product; the following is a list of said peaks:
δTMS (ppm) : 74.9 (d); 70.5 (d); 31.4 (t); 29.0 (t); 28.9 (t); 28.8 (t); 28.6 (t); 26.9 (t); 24.8 (t); 22.8 (q); 22.4 (t); 22.0 (t); 14.3 (q).)
(g) retention coefficients (Rf) in thin-layer chromatography and retention times (Rt) on a reverse-phase HPLC column, respectively, as reported under paragraphs (g) and (h) of the description of the physico-chemical characteristics of antibiotic AB-011a.
(h) a diagram derived from a thermogravimetric analysis carried out under nitrogen, with a temperature increase rate of 20°C/minute within the temperature range of from 30°C to 700°C, on a PERKIN-ELMER 7 SERIES Thermal Analysis System, said plot being shown in Figure 10, in which on the abscissa the temperature is given in °C, and on the ordinate the percent weight loss is indicated. In said Figure 10 also the first derivative of the curve is shown. - The microorganism was isolated from a sample of soil collected at Varzo (Novara), catalogued under the designation SD18.
- A culture of this microorganism was deposited on January 22nd, 1988, in compliance with the Budapest Treaty, with the National Collection of Industrial Bacteria (c/o the National Collection of Industrial and Marine Bacteria Ltd., Torry Research Station, P.O.Box 31, 135 Abbey Road, Aberdeen AB 98 DG, Scotland, United Kingdom), where it was given the access number NCIB 12629.
- The morphological characteristics of the strain are listed in Table A (the names of the culture media are those assigned by the International Streptomyces Program).
Table A ISP Code Culture Medium Description M2 Malt Extract Agar High, rough colonies with a base mycelium of light colour, the spores are plentiful and are of light yellow colour. M3 Oat Meal Agar Low colonies, "radiated" base mycelium of light colour, white spores. M4 Starch Agar Scarce growth, white spores. M5 Glycerol Asparagine Agar Scarce growth, white spores. M6 Peptone Iron Agar Not very high colonies, light-coloured mycelium, white spores. M7 Tyrosine Agar High colonies, base mycelium of brown colour, gray spores; formation of an intense melanoid pigment. -- Nutrient Agar Large, high, rough colonies, with yellow spores. -- Dextrose Potato Agar High colony, base mycelium of orange colour, spores of light gray colour; intense, diffused melanoid pigment. -
- In Table C, the growth of the strain on some organic substances as the only source of carbon is reported.
Table C Compound Growth 2-keto-gluconate negative adonitol negative arabinose negative cellobiose negative fructose positive galactose negative glycerol positive glucose positive inositol positive lactose negative maltose negative mannitol positive melezitose negative methyl-D-glucoside negative N-acetyl-D-glucosamine positive raffinose negative rhamnose positive saccharose negative sorbitol negative trehalose positive xylitol negative xylose negative - The analysis of the cellular wall of SD18 strain carried out according to the method described by M.P. Starr, H. Stolp, H.G. Truper, A. Ballows, H.G. Shegel (The Prokaryotes - Vol.II Streptomycetacee - Springer Verlag Ed., 1981) demonstrates the absence of characteristic sugars; thus it confirms that SD18 belongs to the Streptomyces genus.
- Like other microorganisms, Streptomyces s.p. NCIB 12629 can undergo mutations.
- For example, artificial variants or mutants can be obtained by treatment with various known mutagens, such as X rays or U.V. light, high-frequency waves and chemical substances, like nitrous acid, halogenated alkylamines, nitroso-guandine, camphor, and the like.
- All of the variants or mutants, both of natural origin and man-made, which belong to the genus Streptomyces and produce AB-011 antibiotics are considered to be equivalent to Strepromyces s.p. strain NCIB 12629 and are comprised within the scope of the present invention.
- The process for the preparation of AB-011 antibiotics comprises the cultivation of Streptomyces s.p. NCIB 12629, or of an equivalent mutant thereof, under conditions of controlled aerobic fermentation in an aqueous nutrient medium, and the subsequent separation of said antibiotics by means of per se known methods.
- As nutrient culture media or fermentation broths those which are commonly employed for the production of antibiotics can be used; however, some culture media are preferred.
- Said cultivation media should contain sources of carbon and nitrogen which can be assimilated by the microorganisms of the genus Streptomyces, and should, furthermore, show low levels of inorganic salts. Additionally, the media should contain traces of those metals which are necessary for the growth and the development of the microorganisms. Said metals may already be present as impurities in the sources of carbon or of protein nitrogen supplied for the bacterial growth or, optionally, they can be added to the culture medium.
- As carbon source there can be used carbohydrates which may be of the saccaride type, such as, e.g., glucose or fructose, and of the starch type, or products similar to those types from an industrial point of view, such as, e.g. dextrin, soluble starch, or polyalcohols, such as, e.g. glycerol. Said compounds can be used either individually or in combination.
- The concentration of the carbon source in the culture medium generally depends on the type and amount of the other ingredients contained in said medium; anyway, concentrations of from 0.5 to 5% by weight are generally satisfactory. As nitrogen source both proteinic extracts such as, e.g., yeast extract, casein hydrolisate, or peptone, and meals, such as, e.g. soybean meal, or commercially available industrial pro ducts for that purpose, such as, e.g., proflo, corn steep liquor or distillers' solubles, can be used.
- These compounds can be used individually or in combination, at concentrations in the culture medium of from 0.1% to 4% by weight.
- As inorganic salts there can be used, for example, sodium salts, potassium salts, magnesium salts, ammonium salts and calcium salts, such as phosphates, sulfates, chlorides, carbonates and nitrates.
- The trace metals can be, e.g., cobalt, manganese, iron, and the like.
- Some culture media display a particular ability to stimulate the production of AB-011 antibiotics by Streptomyces s.p. NCIB 12629; among these, for example, the following aqueous formulations can be mentioned, which have been employed in the following preparation Examples.
P CULTURE MEDIUM Ingredients Concentration g/ l starch 20 glucose 10 calcium carbonate 3 casein hydrolysate 2 proflo (cotton seed flour) 2 yeast extract 2 meat extract 2 V CULTURE MEDIUM Ingredients Concentration g/ l tryptone 10 meat and liver peptone 10 glucose 5 yeast extract 5 K₂HPO₄ 1 S CULTURE MEDIUM Ingredients Concentration g/l soluble starch 10 glucose 5 potassium nitrate 2 sodium chloride 2 monobasic potassium phosphate 2 hydrolysed casein 1 calcium carbonate 1 magnesium sulfate heptahydrate 0.5 iron sulfate heptahydrate 0.01 - The strain of Streptomyces s.p. NCIB 12629 can be cultivated at temperatures of from 20°C to 35°C, preferably of from 25°C to 30°C.
- The pH value generally is within the range of from about 5 to about 9.
- The sterile air which is injected into the culture medium is generally used in such amounts as to maintain in the medium an oxygen concentration equal to, or higher than, 20% of the saturation value.
- The production of the antibiotics, during the fermentation, can be monitored by means of antibiotic activity tests on broth samples.
- The fermentation is carried out for a time sufficient for obtaining a substantial antibiotic activity; 72-120 hours are generally sufficient for that purpose.
- After the cultivation under the above fermantation conditions, the AB-011 antibiotics and the main components thereof, i.e. antibiotics AB-011a and AB-011b, can be separated from the culture broth and subsequently purified by means of methods conventional in the art of fermentation.
- Such methods include, e.g., extraction with solvents, precipitation with non-solvents, ultrafiltration, column chromatography, silica-gel chromatography, cellulose chromatography, reverse-phase chromatography, chromatography on non-ionic, macroporous resins, and the like.
- The antibiotics produced during the fermentation can be found in the culture broth and/or in the mycelium mass.
- A preferred method for recovering the AB-011 antibiotics consists in filtering off the mycelium mass from the culture broth, subjecting the mycelium thus separated to an extraction with acetone or methanol and concentrating the extract under vacuum until complete removal of the solvent. Thereby an aqueous suspension is obtained, while suspension is combined with the culture broth.
- The resulting solution containing the AB-011 antibiotics is filtered through fibreglass-paper filters and is then percolated on a column of a non-ionic polystyrene resin, such as, e.g., XAD-2 (Rohm & Haas Co.), which resin adsorbs the AB-011 antibiotics.
- The resin is then washed with two volumes, based on its bed, of water, and thereafter is eluted with three volumes, also based on its bed, of an 8:2 (V/V) mixture of acetone:water.
- The fractions containing the AB-011 antibiotics, identified by means of biological activity tests on Botrytis, are combined and are then concentrated to dryness under vacuum, affording a crude product containing the AB-011 antibiotics, substantially composed of AB-011a and AB-011b.
- Both pure AB-011a and pure AB-011b are then isolated from the crude product by means of reverse phase chromatography, employing a column packed with silica (MATREX Silica C18 marketed by Amicon Europe, Lausanne, Switzerland) with an eluent system formed by an eluent "A" consisting of water containing 25 millimol per litre of KH₂PO₄ and 7 millimol per litre of tetramethylammonium chloride, and by an eluent "B" consisting of methanol, using a linear gradient of from 50% up to 80% of eluent "B" in eluent "A".
- The fractions which contain antibiotic AB-011a in pure form and antibiotic AB-011b in pure form are separately concentrated under vacuum until complete removal of methanol. By cooling the remaining aqueous solutions down to 2°C, the precipitation of AB-011a and AB-011b, resp. - which are centrifuged off - is achieved.
- AB-011a and AB-011b separated from their respective solutions as described above are suspended in water and centrifuged again and, after removing the supernatant solutions and drying under vacuum at 40 C for 2 hours, pure antibiotic AB-011a and pure antibiotic AB-011b antibiotic, resp., are obtained.
- The AB-011 antibiotics, and the components thereof, i.e., AB-011a and AB-011b, are endowed with antimicrobial activity and, particularly, antifungal activity.
- Their antifungal activity is particularly high against phytopathogenic fungi which infest herbaceous, arboricultural, industrial and horticultural cultivations.
- The antimicrobial activities, both in vitro and in vivo, of AB-011 antibiotics were determined by means of the methods described in the following.
- The antimicrobial activity of AB-011 antibiotics was determined by the usual methods, by means of suitable dilutions in liquid growth medium.
- In Table D, the minimum inhibiting concentrations are set forth.
- For phytopathogenous fungi, the minimum concentration of the AB-011 antibiotics which, under controlled conditions in agarized medium, caused a reduction in mycellar growth of 90% with respect to the control, was determined.
Table D Microorganism Minimum concentration of AB-011 Antibiotics (µg/ml) Botrytis cinerea 17 Cercospora beticola 100 Cercosporella herpotrichoides 30 Colletotrichum coffeanum 30 Fusarium moniliforme 30 Fusarium roseum 8 Helminthosporium gramineum 100 Helminthosporium teres 1.5 Helminthosporium sativum 3 Piricularia oryzae 25 Pythium irregulare 100 Rhizoctonia solani 20 Sclerotium cepivorum 3 Septoria nodorum 6 Ustilago maydis 20 Candida albicans 3.5 Sarcina lutea 0.3 - The fungicidal activity in vivo was measured by the following method. The AB-011 antibiotics in water-acetone solution (20% V/V) were sprayed onto the lower sides of leaves of plants grown in pots inside a conditioned room.
- One day later, an inoculum of the tested fungus was sprayed on the upper sides of the plant leaves. These plants were then kept under incubation conditions inside a conditioned room for about eight days.
- At the end of said time, the seriousness of the infection was evaluated by means of an evaluation scale ranging from 100 (= healthy plant) down to 0 (= completely infected plant).
- The data as to the preventive activity in vivo is reported in Table E.
Table E Fungus AB-011 Antibiotics concentration, g/l Preventive activity Plasmopara viticola 0.5 100 0.125 100 0.06 100 Sphaeroteca fuliginea 0.5 85 0.125 40 0.06 0 Botrytis cinerea 0.5 100 0.125 70 0.06 15 - Strictly analogous results of antifungal activity were obtained when the individual antibiotics AB-011a and AB-011b were used.
- For their practical application, both in agriculture and in other sectors of use, the antibiotics according to the present invention are preferably employed in the form of suitable compositions.
- These compositions contain, beside an antibiotic according to the present invention as their active principle, inert solid carriers (e.g., kaolin, silica, talc, attapulgite, diatomaceous earth, etc.), or inert liquid carriers (organic solvents, vegetable or mineral oils, water and mixtures thereof), and possibly other additives which are conventionally used in the art of formulations, such as surfactants, suspending agents, dispersants and wetting agents.
- In case of particular application requirements, or in order to expand the range of action of the compositions, other active ingredients, such as other insecticides, herbicides, fungicides, or fertilizers can be added to the present compositions.
- The applied doses vary as a function of different factors, such as the type and the degree of infestation, the type of composition used and climatic and environmental factors.
- For practical use in agriculture, doses of the present antibiotics of from 10 to 500 g/ha yield satisfactory results.
- The following examples serve to illustrate the present invention without limiting it.
- An ampoul containing 5 ml of the culture of Streptomyces s.p. NCIB 12629 in the above medium "V" (stored in glycerol at 10% and at -20°C) was used to inoculate 150 ml of medium "V". Said medium was then incubated for 72 hours on a rotary shaker (150 rpm) at 28°C.
- The resulting culture was used to inoculate a fermenter (
volume 10 litres) containing 7 litres of medium "S" to which 0.01 g/l ofTween 2000 were added as antifoaming agent, under the following conditions: temperature 29°C,air flow rate 120 litres/hour, rate of stirring 320 rpm, fermentation time 96 hours. - The resulting fermentation broth was filtered through paper and the mycelium was separated.
- For the subsequent purification operations a total volume of 28 l, obtained from four fermentations carried out under the above conditions, was used.
- 28 litres of fermentation broth were filtered through a Whatman GF/D fibreglas filter and the separated mycelium was then extracted with acetone.
- The acetone extract was concentrated under vacuum until the solvent was completely removed and the residual aqueous solution was combined with the previously filtered broth.
- The resulting solution was ultrafiltered through a GR-61 membrane (cut-off 20,000), until 3.2 litres remained in the retained fraction.
- The retained fraction was then diluted to 25 litres with water, and was ultrafiltered again, under the same conditions, whereby a volume of permeate of 20.5 litres was obtained. The second retained fraction (4.0 litres), was scarcely active in the activity test (the activity was determined by measuring the Botrytis growth inhibition halo over agar) and therefore was discarded.
- The first ultrafiltrate of 25 litres was concentrated on a GR-90 membrane (cut-off 2000), until 3.6 l remained in the retained fraction, while the ultrafiltrate (21.0 l) was scarcely active on Botrytis and was discarded. The retained fraction contained 60% of the initial activity.
- The second ultrafiltration permeate (20.5 l) was concentrated on a GR-90 membrane (cut-off 2000) in the same way as described above, and the residual 3.0 litres contained about 30% of the initial activity.
- The GR-61 and GR-90 membranes belong to the types sold by DDS-Nakskov (Danmark) and were used on a Lab-20 module also marketed by said company.
- The two retained fractions (3.6 l + 3.0 l) were combined and percolated on a column (diameter 45 mm; height of resin bed 30 cm) of non-ionic polystyrene resin XAD-2 (Rohm & Haas Co.), which adsorbed the AB-011 antibiotics. During the percolation, an inlet flow rate of 100 ml/hour was maintained. The resin subsequently was washed with two volumes, based on its bed, of water, and was then eluted with 3 volumes, also based on its bed, of an (8:2 V/V) acetone/water mixture.
- The fractions which contained AB-011 antibiotics, identified by means of biological tests carried out on Boytrytis, were combined and concentrated to dryness under vacuum, affording a crude material containing AB-011 antibiotics especially composed of AB-011a and AB-011b.
- The crude product was taken up in 300 ml of methanol, to which 300 ml of water were subsequently added. Pure AB-011a and pure AB-011b were then isolated from the crude material by means of a reverse-phase chromatography, using a column filled with 350 g of silica (MATREX Silica C18, Amicon Europe, Lausanne, Switzerland) and an eluent system formed by eluent "A" (composed of water containing 25 mM
monobasic potassium phosphate 7 mM tetramethyl-ammonium chloride) and eluent "B" (containing methanol), employing a gradient according to the following Table:Composition of the eluent system A/B (V/V) Volume of the eluent system ml 1/1 500 45/55 150 40/60 150 35/65 150 30/70 150 25/75 150 20/80 2000 - Pure AB-011a was collected in a volume of 320 ml in the elution range between 3000 and 3320 ml, while AB-011b was collected in a volume of 700 ml in the elution range between 3700 and 4400 ml.
- The fractions thus obtained were evaporated under vacuum until methanol was completely removed and then were left to stand for 24 hours at 4°C. From these solutions, AB-011a and AB-011b, respectively precipitated and were collected by centrifugation; then they were suspended again in water and centrifuged.
- After drying, 70 mg of antibiotic AB-011a, as a light yellow-coloured powder, and 20 mg of antibiotic AB-011b, as a deep yellow coloured powder, were obtained.
- The physico-chemical characteristics of the products have been indicated above.
- A freeze-dried ampoul of Streptomyces s.p., strain NCIB 12629, was opened under aseptic conditions and rehydrated with sterile distilled water. The resulting suspension was used to inoculate a 500 ml Erlenmeyer flask containing 100 ml of culture medium "P", described above, which was then incubated for 90 hours on a rotary shaker (180 rpm) at 28°C.
- At the end of this time, the culture broth was centrifuged in order to separate it from the mycelium, and was then used for the biological tests.
- A freeze-dried ampoul of Streptomyces s.p., strain NCIB 12629, was rehydrated and used to inoculate the culture medium "P", as described in Example 2.
- The culture was incubated for 72 hours on a rotary shaker (180 rpm) at 28 C.
- 5 ml of the obtained culture were used to inoculate a 500 ml Erlenmeyer flask containing 100 ml of culture medium "S" (SCM), described above, which was then incubated for 120 hours on a rotary shaker (180 rpm) at 28°C.
- At the end of this time, the culture broth was treated and used in the biological tests in the manner described in Example 2.
- A 100 ml Erlenmeyer flask containing 25 ml of culture medium "P" (PMB) as described above was inoculated with a portion of a colony of the Streptomyces s.p. strain NCIB 12629, drawn under aseptic conditions from a plate, or from a slant or agarized "P" medium.
- This culture then was incubated for 72 hours on a rotary shaker (180 rpm) at 28°C. Thereafter the incubated culture was inoculated in a 100 ml Erlenmeyer flask containing 20 ml of the "P" medium up to a concentration of 5% and the whole mixture was incubated for 120 hours under the conditions given in Ex ample 2.
- At the end of this time, the culture broth was treated in the same way as described in Example 2 and was subjected to the biological tests.
(h) a retention time (Rt) of about 7 minutes when subjected to reverse-phase HPLC column chromatography under the following conditions: (Under the same conditions antibiotic AB-011b was eluted after about 9 minutes.)
(i) a good solubility in dimethylsulfoxide and in (1:1 V/V) ethanol/water or (1:1 V/V) methanol/water mixtures (V/V = volume/volume), poor solubility in water, fairly good solubility in ethanol and methanol;
(j) a diagram derived from a thermogravimetric analysis carried out under nitrogen, with a temperature increase rate of 20°C/minute within the temperature range of from 30°C to 700°C, on a PERKIN-
Claims (12)
2.269 at 350.4 nm; 2.197 at 332.6 nm; 1.403 at 317.3 nm; 0.679 at 303.3 nm; 0.118 at 381.1 nm and 0.097 at 405.6 nm at a concentration of 0.029 mg/ml in methanol;
δTMS (ppm) 6.45-6.10* (m, 8H); 5.92 (m, 1H); 5.69 (m, 1H); 5.41 (m, 2H); 5.15 (m, 1H), 4.92 (m, 1H); 4.77-4.22 (m, 6H); 4.22-3.45* (m, 8-10H); 3.37-3.07* (m, 6-7H); 3.02 (t,1H); 2.93 (t, 1H); 2.88-2.72* (m, 3H); 2.45-2.27* (m, 3-4H); 2.27-2.05* (m, 3H); 2.05-1.85* (m, 3H); 1.85-1.66* (m, 1H); 1.66-1.15* (m, 30-33H); 1.10 (d, 3H); 0.99 (d, 3H); 0.90 (m, 6H);
δTMS (ppm) : 208.6 (s); 176.3 (s); 170.3 (s); 135.8 (d); 134.6 (d); 133.5 (d); 133.2 (d); 132.9 (d); 132.7 (d); 131.7 (d); 131.4 (d); 130.0 ( d); 129.5 (d); 100.3 (d); 99.8 (d); 97.4 (s); 97.3 (d); 87.1 (d); 84.4 (d); 79.9 (d); 75.0 (d); 73.5 (d); 73.1 ( d); 72. 1 (d); 70.7 (d); 70.0 (d); 69.0 (d); 67.1 (d); 66.1 (d); 65.9 (d); 64.0 (d); 58.1 (d); 56.9 (q); 56.3 (d); 51.6 (t); 50.5 (t); 44.7 (t) 43.0 (t); 42.5 (t); 39.7 (d); 39.4 (d); 39.0 (t); 37.5 (t); 36.3 (t); 34.4 (t); 32.1 (t); 31.7 (t); 29.3 (t); 18.0 (q); 17.9 (q); 17.1 (q); 16.0 (q); 11.5 (q);
Rf values obtained by reverse-phase chromatography on plates of the type RP-18F 254 (Merck-Schuchardt) of: in a methanol/aqueous solution containing 25 mM
2.872 at 349.9 nm; 2.747 at 332.4 nm; 1.999 at 316.9 nm; 0.987 at 303.3 nm; at a concentration of 0.04 mg/ml in methanol;
3415, 2926, 2855, 2060, 1721, 1634, 1568, 1450, 1406, 1383, 1302, 1264, 1190, 1168, 1063, 1036, 1007, 988, 906, 847, 804, 722, 664, 618, 576, 509, 471, 446 cm⁻¹;
δTMS (ppm) : 6.45-6.05 (m, 8H); 5.93 (m, 1H); 5.70 (m, 1H); 5.40 (m, 2H); 5.13 (m, 1H); 4.73-4.30 (m, 6H); 4.27-3.45* (m, 8-9H); 3.37-3.09* (m, 6-7H); 3.02 (t, 1H); 2.94 (t, 1H); 2.75-2.60* (m, 1H); 2 44-2.28* (m, 3H); 2.28-1.81*(m, 7-8H); 1.81-1.47* (m, 5H); 1.47-1.16* (m, 30-33H). 1.1 (d, 3H). 0.99 (d, 3H), 0.91 (m. 6H);
δTMS (ppm) 208.7 (s); 176.3 (s); 174.9 (s). 170.4 (s); 135.7 (d); 134.7 ( d); 133.5 (d); 133.3 (d); 132.9 (d); 132 .7 (d); 131 .7 ( d); 131.5 (d); 130.0 (d); 129.5 (d); 103.3 (d); 100.0 (d); 97.4 (s); 96.9 (s); 87.2 (d); 84.5 (d); 80.0 (d); 75.1 (d); 74.9 (d); 73.1 (d); 72.2 (d); 70.7 (d); 70.0 (d); 69.0 (d); 68.5 (d); 67.8 (d); 67.1 (d); 85.9 (d); 65.7 (d); 63.9 (d); 58. 1 (d); 56.9 (q); 56.2 (d); 51.5 (t); 50.7 (t); 46.5 (t); 44.7 (t); 42.5 (t); 39.1 (t); 38.5 (t); 38.0 (t); 36.3 (t); 34.1 (t); 32.3 (t); 31.8 (t); 31.6 (t); 29.3 (t); 18.1 (q); 18.0 (q); 17.9 (q); 17.4 (q); 16.3 (q); 11.6 (q);
Rf values obtained by reverse-phase chromatography on plates of the type RP-18F 254 (Merck-Schuchardt) of:
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2095688 | 1988-06-14 | ||
IT8820956A IT1234197B (en) | 1988-06-14 | 1988-06-14 | ANTIBIOTICS OBTAINED THROUGH AEROBIC CULTIVATION CONTROLLED BY STREPTOMYCES S.P. NCIB 12629 |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0346831A2 true EP0346831A2 (en) | 1989-12-20 |
EP0346831A3 EP0346831A3 (en) | 1991-03-27 |
EP0346831B1 EP0346831B1 (en) | 1995-02-22 |
Family
ID=11174598
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP89110689A Expired - Lifetime EP0346831B1 (en) | 1988-06-14 | 1989-06-13 | Antibiotics and process for producing them |
Country Status (12)
Country | Link |
---|---|
US (1) | US5153127A (en) |
EP (1) | EP0346831B1 (en) |
JP (1) | JP2839032B2 (en) |
KR (1) | KR970010955B1 (en) |
AT (1) | ATE118780T1 (en) |
AU (1) | AU617820B2 (en) |
CA (1) | CA1338170C (en) |
DE (1) | DE68921252T2 (en) |
ES (1) | ES2068849T3 (en) |
IL (1) | IL90575A (en) |
IT (1) | IT1234197B (en) |
ZA (1) | ZA894440B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6464484B1 (en) | 2002-03-30 | 2002-10-15 | Q2100, Inc. | Apparatus and system for the production of plastic lenses |
AR040324A1 (en) * | 2002-12-10 | 2005-03-30 | Coca Cola Femsa De Buenos Aire | COMPOSITION OF MEANS OF CULTURE FOR FUNGI AND YEAST, METHOD OF PREPARATION AND USES OF SUCH COMPOSITION |
GB0814830D0 (en) * | 2008-08-13 | 2008-09-17 | Univ Cardiff | Antimicrobial agent and method for the production thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3689639A (en) * | 1969-01-23 | 1972-09-05 | Malcolm E Bergy | Antibiotic berninamycin and process for making same |
US4397950A (en) * | 1981-11-23 | 1983-08-09 | The Upjohn Company | Process for production of antibiotic U-64,767 using Streptomyces macronensis NRRL 12566 |
US4540661A (en) * | 1983-02-24 | 1985-09-10 | The Upjohn Company | Composition of matter and process |
US4534965A (en) * | 1983-09-26 | 1985-08-13 | Chevron Research Company | Controlling plant fungi using streptomycetes grown on chitin |
DE3604678A1 (en) * | 1986-02-14 | 1987-09-03 | Hoechst Ag | NEW STREPTOGRAMINE-TYPE ANTIBIOTICS, A MICROBIOLOGICAL PROCESS FOR THEIR PRODUCTION AND THEIR USE AS MEDICINAL PRODUCTS AND FEED ADDITIVES |
GR870397B (en) * | 1986-03-12 | 1987-07-10 | Glaxo Group Ltd | Macrolide compounds |
NZ222895A (en) * | 1986-12-15 | 1992-08-26 | Lilly Co Eli | Streptomyces gardneri strains and production of antibiotic a10255 complex and factors b, c, e, f and g; animal feed and pharmaceutical compositions |
-
1988
- 1988-06-14 IT IT8820956A patent/IT1234197B/en active
-
1989
- 1989-06-12 IL IL90575A patent/IL90575A/en not_active IP Right Cessation
- 1989-06-12 ZA ZA894440A patent/ZA894440B/en unknown
- 1989-06-13 DE DE68921252T patent/DE68921252T2/en not_active Expired - Fee Related
- 1989-06-13 CA CA000602620A patent/CA1338170C/en not_active Expired - Fee Related
- 1989-06-13 ES ES89110689T patent/ES2068849T3/en not_active Expired - Lifetime
- 1989-06-13 EP EP89110689A patent/EP0346831B1/en not_active Expired - Lifetime
- 1989-06-13 AU AU36298/89A patent/AU617820B2/en not_active Ceased
- 1989-06-13 AT AT89110689T patent/ATE118780T1/en not_active IP Right Cessation
- 1989-06-14 JP JP1152063A patent/JP2839032B2/en not_active Expired - Lifetime
- 1989-06-14 KR KR1019890008222A patent/KR970010955B1/en not_active IP Right Cessation
-
1991
- 1991-12-03 US US07/800,737 patent/US5153127A/en not_active Expired - Fee Related
Non-Patent Citations (1)
Title |
---|
No relevant documents have been disclosed. * |
Also Published As
Publication number | Publication date |
---|---|
ZA894440B (en) | 1990-02-28 |
AU3629889A (en) | 1989-12-21 |
CA1338170C (en) | 1996-03-19 |
DE68921252D1 (en) | 1995-03-30 |
IL90575A0 (en) | 1990-01-18 |
KR900000480A (en) | 1990-01-30 |
KR970010955B1 (en) | 1997-07-05 |
IT8820956A0 (en) | 1988-06-14 |
ES2068849T3 (en) | 1995-05-01 |
IT1234197B (en) | 1992-05-06 |
EP0346831B1 (en) | 1995-02-22 |
JPH0242095A (en) | 1990-02-13 |
AU617820B2 (en) | 1991-12-05 |
IL90575A (en) | 1993-08-18 |
ATE118780T1 (en) | 1995-03-15 |
JP2839032B2 (en) | 1998-12-16 |
DE68921252T2 (en) | 1995-09-28 |
US5153127A (en) | 1992-10-06 |
EP0346831A3 (en) | 1991-03-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2012274A1 (en) | New process for producing immunosuppressant agent | |
WO1994023056A1 (en) | Process for isolating a83543 and its components | |
EP0371509B1 (en) | Antibiotics and process for producing them | |
EP0300273B1 (en) | AB-006 antibiotics and process for their production | |
EP0346831A2 (en) | Antibiotics and process for producing them | |
FI81834C (en) | New agricultural chemical called "substance no. 51262", as well as its preparation | |
US5397570A (en) | Antibiotics AB-023 and process for preparing them | |
SU1296009A3 (en) | Micromonospora sp.nrrl 15118 starin - producer of producer of antibiotic complex and method for producing antibiotic complex | |
EP0545490B1 (en) | Antibiotic AB-041 and the process for its production | |
CA1209068A (en) | Physiologically active substances ss 12538, their preparation and a novel microorganism producing same | |
JP2868237B2 (en) | Novel bioactive substance OM-6519 and production method thereof | |
JPS5913190B2 (en) | Antibiotic C-11924F-1 | |
EP0033624B1 (en) | Antitoxic substance, process for its preparation and microorganism used | |
JP2990628B2 (en) | New plant growth regulating substance aji-302 and its production | |
CA2090491A1 (en) | Antibiotic ge1655 complex and its factors a, b and c | |
JPS61289005A (en) | Plant pathogenic germ sporulation inhibitor | |
DE2115295A1 (en) | Protease inhibitors prepn | |
JPS63255292A (en) | Antibiotic rk-16 and production thereof | |
JPS63280073A (en) | Novel antibiotic yp-02978l-c and production thereof | |
JPS6167492A (en) | Novel antibiotic substance ss21020a and its preparation | |
JPH07304622A (en) | New insecticidally active substance sf 2,775 substance, its production and insecticide comprising the same as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE CH DE ES FR GB LI NL SE |
|
PUAL | Search report despatched |
Free format text: ORIGINAL CODE: 0009013 |
|
AK | Designated contracting states |
Kind code of ref document: A3 Designated state(s): AT BE CH DE ES FR GB LI NL SE |
|
17P | Request for examination filed |
Effective date: 19910620 |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIENT |
|
17Q | First examination report despatched |
Effective date: 19930629 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE ES FR GB LI NL SE |
|
REF | Corresponds to: |
Ref document number: 118780 Country of ref document: AT Date of ref document: 19950315 Kind code of ref document: T |
|
ET | Fr: translation filed | ||
REF | Corresponds to: |
Ref document number: 68921252 Country of ref document: DE Date of ref document: 19950330 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2068849 Country of ref document: ES Kind code of ref document: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 19990414 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 19990609 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 19990610 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 19990614 Year of fee payment: 11 Ref country code: CH Payment date: 19990614 Year of fee payment: 11 Ref country code: AT Payment date: 19990614 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 19990621 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 19990628 Year of fee payment: 11 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 19990819 Year of fee payment: 11 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000613 Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000613 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000614 Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000614 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000630 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000630 Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000630 |
|
BERE | Be: lapsed |
Owner name: MINISTERO DELL' UNIVERSITA' E DELLA RICERCA SCIEN Effective date: 20000630 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20010101 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20000613 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
EUG | Se: european patent has lapsed |
Ref document number: 89110689.0 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20010228 |
|
NLV4 | Nl: lapsed or anulled due to non-payment of the annual fee |
Effective date: 20010101 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20010403 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20010712 |